Repurposing FDA-Approved MEK Inhibitor Trametinib for Protection Against Cisplatin-Induced Hearing Loss
重新利用 FDA 批准的 MEK 抑制剂 Trametinib 以预防顺铂引起的听力损失
基本信息
- 批准号:10552555
- 负责人:
- 金额:$ 5.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-10 至 2023-10-27
- 项目状态:已结题
- 来源:
- 关键词:AdultAffectAntineoplastic AgentsAuditoryAuditory Brainstem ResponsesAwardBRAF geneBloodCell LineCell physiologyCellsCenters of Research ExcellenceCisplatinClinical TrialsCochleaCollaborationsCore FacilityDataDiseaseDisease remissionDoseDrug CombinationsEarEnvironmentEquipmentGrantHair CellsHearingInbred CBA MiceIndividualJointsLaboratoriesLabyrinthLanguageLanguage DevelopmentLifeMEKsMalignant NeoplasmsMass Spectrum AnalysisMeasuresMediatingMetastatic malignant neoplasm to brainMitogen-Activated Protein Kinase InhibitorMitogen-Activated Protein KinasesModelingMorphologyMusNeuronsOralPathway interactionsPatientsPerilymphPhosphorylationPlayProtein KinaseQuality of lifeRegulationResearchRoleSamplingScientistSpectrometryStria VascularisSupporting CellTestingTherapeuticTherapeutic AgentsTherapeutic EffectToxic effectTranslatingTumor PromotionUnited States Food and Drug AdministrationUnited States National Institutes of HealthWorkZebrafishalternative treatmentanti-cancerblood-brain barrier crossingcancer therapycareerchemotherapeutic agentchemotherapycisplatin induced hearing lossclinically relevantdrug testinghearing impairmentin vivoinhibitorkinase inhibitormeetingsmelanomamouse modelnovelotoacoustic emissionototoxicitypreclinical trialpreventrecruitresearch facultyside effectspiral gangliontherapeutic candidatetherapeutic targettreatment strategytumor
项目摘要
Project Summary/Abstract
Hearing loss caused by cisplatin ototoxicity affects 40-60% of chemotherapy patients resulting in decreased
quality-of-life and debilitating language barriers, yet no Food and Drug Administration (FDA)-approved
treatment is currently available. Current compounds in preclinical and clinical trials provide only partial
protection or are associated with life-threatening side effects, thus there is a clear need alternative treatment
strategy. Recently, BRAF inhibitor dabrafenib was found to protect from cisplatin toxicity in vivo when
administered at clinically relevant doses. Additional inhibitors of the mitogen-activated protein kinase (MAPK)
pathway, including MEK inhibitor trametinib, also protect from cisplatin toxicity in cochlear explant models.
Importantly, a combination of dabrafenib and trametinib is FDA-approved for treatment of melanoma and may
be fast-tracked for treatment cisplatin-induced hearing loss. The compounds are also effective against brain
metastases, revealing they cross the blood-brain barrier which is similar to the blood-labyrinth barrier in the
ear. We therefore hypothesize trametinib will protect against cisplatin-induced ototoxicity in vivo and
provide enhanced protection in combination with dabrafenib. In aim 1, we will determine whether MEK
inhibitor trametinib confers protection from cisplatin-induced ototoxicity in mouse models. We will test whether
oral trametinib mitigates cisplatin ototoxicity in CBA mouse models using a clinically relevant multi-dose, multi-
cycle treatment model. Hearing loss will be determined by measuring auditory brainstem response (ABR) and
distortion product otoacoustic emission (DPOAE) threshold shifts, along with morphological analysis of
cochlear HCs, supporting cells, stria vascularis, and SGNs. Verification of trametinib-mediated MAPK pathway
inhibition will be obtained by immunostaining of adult mouse cochleae. Confirmation trametinib crosses the
blood-labyrinth barrier achieved by above mentioned immunostaining and Mass Spectrometry (LC-MS) of
perilymph samples from trametinib treated mice. In aim 2, determine if a combination of trametinib and
dabrafenib provide enhanced protection from cisplatin-induced ototoxicity We will test the drug combination’s
protection from ototoxicity, regulation of the MAPK pathway, and ability to cross the blood-labyrinth barrier as
described in aim 1. This study will be the first to investigate the potential of trametinib, and combination of
trametinib with dabrafenib, for protection against cisplatin-induced hearing loss as we seek to provide a robust
therapeutic candidate for a disorder with no current FDA-approved treatment. Moreover, Creighton hosts 7
auditory research labs who regularly collaborate on projects, joint meetings, and seminars. Additionally,
Creighton’s Translational Hearing Center has been awarded an NIH-affiliated Centers of Biomedical Research
Excellence (COBRE) grant to translate basic hearing loss research into practical therapies. It will allow for
expansion of core facility equipment as well as recruit new research faculty. Thus, Creighton provides an
excellent environment and support for junior scientists seeking to build a career in the auditory research field.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Matthew A Ingersoll其他文献
Matthew A Ingersoll的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Matthew A Ingersoll', 18)}}的其他基金
Repurposing FDA-Approved MEK Inhibitor Trametinib for Protection Against Cisplatin-Induced Hearing Loss
重新利用 FDA 批准的 MEK 抑制剂 Trametinib 以预防顺铂引起的听力损失
- 批准号:
10389136 - 财政年份:2022
- 资助金额:
$ 5.47万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 5.47万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 5.47万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 5.47万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 5.47万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 5.47万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 5.47万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 5.47万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 5.47万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 5.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 5.47万 - 项目类别:
Studentship














{{item.name}}会员




